POLICYSTIC OVARIAN SYNDROME AND NITRIC OXIDE. EFFECTS OF TREATMENT WITH N-ACETYLCYSTEINE AND ARGININE
Active, not recruiting
- Conditions
- TO RESTORE A PHYSIOLOGICAL MESTRUAL CICLICITY AND OVULATION INCREASING THE PRODUCTION OF NITRIC OXIDE IN SUBJECTS WITH POLICYSTIC OVARIAN SYNDROME BY MEANS OF ARGININE AND ACETYLCYSTEINE ADMINISTRATIONMedDRA version: 9.1Level: LLTClassification code 10036049Term: Polycystic ovaries
- Registration Number
- EUCTR2005-002091-15-IT
- Lead Sponsor
- AZIENDA SANITARIA OSPEDALIERA S. GIOVANNI BATTISTA DI TORINO
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not Recruiting
- Sex
- Female
- Target Recruitment
- Not specified
Inclusion Criteria
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: INDUZIONE DI UNA FISIOLOGICA CICLICITA' MESTRUALE CON RIPRISTINO DELL'OVULAZIONE <br>;Secondary Objective: RIDUZIONE DEL TASSO DI ANDROGENI CIRCOLANTI; INCREMENTO DELLA SENSIBILITA' PERIFERICA ALL'INSULINA E MIGLIORAMENTO DEL PROFILO LIPIDICO; RIDUZIONE DEI PARAMETRI OSSIDATIVI E MIGLIORAMENTO DEGLI INDICI DI FUNZIONALITA' ENDOTELIALE ;Primary end point(s):
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie nitric oxide enhancement by arginine and N-acetylcysteine in EUCTR2005-002091-15-IT for polycystic ovarian syndrome?
How does arginine/N-acetylcysteine therapy in EUCTR2005-002091-15-IT compare to metformin in restoring ovulation in polycystic ovarian syndrome patients?
Which oxidative stress or eNOS biomarkers predict response to arginine and NAC in the EUCTR2005-002091-15-IT POS trial?
What adverse events were observed in EUCTR2005-002091-15-IT using arginine and N-acetylcysteine for polycystic ovarian syndrome, and how are they managed?
What other NO-boosting compounds or antioxidant therapies are being explored for polycystic ovarian syndrome alongside arginine and N-acetylcysteine in clinical trials?